Literature DB >> 18639097

Diagnosis of cerebral arteriovenous malformations with three-dimensional CT angiography.

S Tanabe1, T Uede, T Nonaka, M Ohtaki, K Hashi.   

Abstract

High speed spiral computed tomography (CT) is well known to be a good tool to visualize cerebrovascular lesions; this technique is called three-dimensional CT angiography (3D-CTA). Although 3D-CTA is widely accepted to diagnose cerebral aneurysms because it is less invasive and more useful than digital subtraction angiography, little is known about its diagnostic potential for arteriovenous malformation (AVM). In this study, the efficacy of 3D-CTA in diagnosis and surgical planning was investigated in 21 patients with AVMs. AVMs located in the cerebral hemisphere, the cerebellum, the basal ganglia, the brain stem, the corpus callosum, the optic chiasm and the lateral ventricle. 3D-CTA clearly demonstrated the three-dimensional feature of the feeding artery, the nidus, the draining vein and the surrounding normal structures. We conclude that 3D-CTA is essential to preoperative planning for the appropriate surgical approach toward the AVM.

Entities:  

Year:  1998        PMID: 18639097     DOI: 10.1016/s0967-5868(98)90008-x

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  Pitfall in CT angiographic planning of cerebral aneurysm therapy.

Authors:  Christian Dorfer; Engelbert Knosp; Andreas Gruber
Journal:  Neuroradiology       Date:  2010-04-13       Impact factor: 2.804

2.  The diagnostic value of three-dimensional CT angiography for patients with acute coronary artery disease.

Authors:  Libo Li; Jing Hao; Shi Qu; Yancheng Fang
Journal:  Exp Ther Med       Date:  2018-06-07       Impact factor: 2.447

3.  Arteriovenous Malformations Treated With Frameless Robotic Radiosurgery Using Non-Invasive Angiography: Long-Term Outcomes of a Single Center Pilot Study.

Authors:  Ryan Kelly; Anthony Conte; M Nathan Nair; Jean-Marc Voyadzis; Amjad Anaizi; Sean Collins; Christopher Kalhorn; Andrew Stemer; Jeffery Mai; Rocco Armonda; Jonathan Lischalk; Frank Berkowitz; Vikram Nayar; Kevin McGrail; Brian Timothy Collins
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.